BioNTech: 1st Patient Dosed in Phase 2 Trial of mRNA-based BNT111 in Advanced Melanoma

 -- First program from BioNTech's fully-owned mRNA cancer vaccine platform

      FixVac treats patients in a randomized clinical Phase 2 clinical trial 
 
   -- Phase 2 trial is based on positive results from Phase 1 Lipo-MERIT trial 
      that demonstrated a favorable safety profile for BNT111 as well as 
      durable objective responses observed in patients with melanoma who had 
      progressed following prior checkpoint blockade 
 
   -- Trial is enrolling a total of 120 patients at clinical trial sites in the 
      European Union, the United Kingdom, the United States and Australia 

https://www.marketscreener.com/quote/stock/BIONTECH-SE-66771992/news/Press-Release-nbsp-BioNTech-Announces-First-Patient-Dosed-in-Phase-2-Clinical-Trial-of-mRNA-based-35641251/